BioSpace News Archive

Business

Neurimmune ATTR-CM Asset Nets Potential $700M Plus From AstraZeneca

AstraZeneca and Neurimmune have signed an exclusive global collaboration and licensing deal to develop, manufacture and commercialize NI006 for ATTR-CM.

March 1, 2022
·
2 min read
·
Vanessa Doctor, RN
Business

J&J, Legend Introduce New CAR-T Therapy, Carvykti to Multiple Myeloma Market

Johnson & Johnson’s partner, Legend Biotech, has been awarded FDA approval for its (CAR-T) therapy, Carvykti, for the treatment of multiple myeloma disease.

March 1, 2022
·
3 min read
·
Hayley Shasteen
Drug Development

FDA Rejects Gilead’s Long-Acting HIV Drug Over Vial Issues

The FDA rejected Gilead’s New Drug Application, citing Chemistry Manufacturing and Controls (CMC) problems associated with the compatibility of the drug with the proposed container vial.

March 1, 2022
·
2 min read
·
Mark Terry
Biotech Bay

Revolution Medicines to Participate in Cowen 42nd Annual Health Care Conference

Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that the company will participate in the Cowen 42nd Annual Health Care Conference.

March 1, 2022
·
1 min read
Business

ChemoCentryx Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights

ChemoCentryx, Inc., (Nasdaq: CCXI), today announced financial results for the fourth quarter and full year ended December 31, 2021 and provided an overview of recent corporate highlights.

March 1, 2022
·
16 min read
Business

Health Catalyst Reports Fourth Quarter and Year End 2021 Results

Health Catalyst, Inc. (“Health Catalyst,” Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today reported financial results for the quarter and year ended December 31, 2021.

March 1, 2022
·
22 min read
Business

Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2021 Financial Results

Jazz Pharmaceuticals plc announced financial results for the full year and fourth quarter of 2021 and provided financial guidance for 2022.

March 1, 2022
·
32 min read
FDA

Amneal Enters U.S. Biosimilars Market With Approval of RELEUKOTM (filgrastim-ayow)

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced the U.S. Food and Drug Administration (FDA) approval of the Biologics License Application (BLA) for filgrastim-ayow, a biosimilar referencing Neupogen®.

March 1, 2022
·
8 min read
Business

NanoString Technologies Releases Fourth Quarter and Full Year 2021 Operating Results and Provides 2022 Financial Outlook

NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today reported financial results for the fourth quarter and year ended December 31, 2021.

March 1, 2022
·
19 min read
Business

Omeros Corporation Reports Fourth Quarter and Year-End 2021 Financial Results

Omeros Corporation (Nasdaq: OMER), today announced recent highlights and developments as well as financial results for the fourth quarter and year ended December 31, 2021.

March 1, 2022
·
20 min read